Technical Analysis for EQ - Equillium, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Fell Below 20 DMA | Bearish | 3.94% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 3.94% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 3.94% | |
Gapped Down | Weakness | 3.94% | |
20 DMA Support | Bullish | 3.53% | |
Outside Day | Range Expansion | 3.53% |
Alert | Time |
---|---|
Possible Inside Day | about 20 hours ago |
Up 5% | about 22 hours ago |
Up 3% | about 22 hours ago |
60 Minute Opening Range Breakout | about 23 hours ago |
Up 2% | about 23 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.25 |
52 Week Low | 0.45 |
Average Volume | 394,413 |
200-Day Moving Average | 0.94 |
50-Day Moving Average | 1.68 |
20-Day Moving Average | 2.55 |
10-Day Moving Average | 2.53 |
Average True Range | 0.34 |
RSI (14) | 61.83 |
ADX | 43.97 |
+DI | 23.58 |
-DI | 15.29 |
Chandelier Exit (Long, 3 ATRs) | 2.24 |
Chandelier Exit (Short, 3 ATRs) | 2.29 |
Upper Bollinger Bands | 2.90 |
Lower Bollinger Band | 2.20 |
Percent B (%b) | 0.63 |
BandWidth | 27.36 |
MACD Line | 0.25 |
MACD Signal Line | 0.29 |
MACD Histogram | -0.047 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.99 | ||||
Resistance 3 (R3) | 2.97 | 2.84 | 2.93 | ||
Resistance 2 (R2) | 2.84 | 2.75 | 2.85 | 2.91 | |
Resistance 1 (R1) | 2.74 | 2.70 | 2.79 | 2.76 | 2.89 |
Pivot Point | 2.61 | 2.61 | 2.64 | 2.62 | 2.61 |
Support 1 (S1) | 2.51 | 2.52 | 2.56 | 2.53 | 2.39 |
Support 2 (S2) | 2.38 | 2.47 | 2.39 | 2.37 | |
Support 3 (S3) | 2.28 | 2.38 | 2.35 | ||
Support 4 (S4) | 2.30 |